Continuous Biopharmaceutical Manufacturing Course

Name: Continuous Biopharmaceutical Manufacturing Training Course
Availability: InStock

Design integrated therapeutic-protein processes with traceability, monitoring, control, validation, and lifecycle evidence.

Continuous Biopharmaceutical Manufacturing Course

At a glance

Duration: 1 Week
Format: Classroom
Cities: Singapore, Lisbon, Nairobi, London, Abu Dhabi, Kuwait and more
Next session: 2 – 6 November 2026, Singapore
Average fee: 7,500 €

Home
Our Categories
Continuous Biopharmaceutical Manufacturing Training Course

Download Brochure (PDF) Print PDF

Overview

Continuous Biopharmaceutical Manufacturing Training Course is a one-week advanced course for manufacturing managers, process engineers, production scientists, quality professionals, validation staff, and technology-transfer teams who leave with a Continuous Biomanufacturing Implementation Dossier. Participants connect ICH Q13 concepts with integrated processing, process dynamics, material traceability, Process Analytical Technology, control strategy, validation, and lifecycle decisions for therapeutic-protein operations. Agile Leaders Training Center presents continuous biopharmaceutical manufacturing through process evidence, control design, and implementation practice.

Who Should Attend

Manufacturing functions responsible for continuous production strategy, capacity, and operating performance
Process engineering functions responsible for integrated unit operations, dynamics, and control design
Production science functions responsible for perfusion, downstream processing, sampling, and process evidence
Quality and validation functions responsible for state of control, risk assessment, verification, and deviation decisions
Technology-transfer functions responsible for process knowledge, scale translation, and site implementation

The course assumes participants already work with bioprocess development or manufacturing data and leaves out introductory biotechnology, equipment operation qualification, and product-specific regulatory advice.

Departments and Industries

The course supports departments and industries that develop, operate, assess, or transfer continuous biopharmaceutical processes.

Biopharmaceutical and therapeutic-protein manufacturing operations
Biotechnology process development and production science teams
Quality assurance, validation, and technical operations departments
Engineering, automation, and manufacturing data functions
Contract development, manufacturing, and technology-transfer organizations

Learning Objectives

By the end of this course, participants will be able to:

Apply ICH Q13 concepts to therapeutic-protein process architecture
Analyze process dynamics and residence-time distribution evidence
Build material traceability, sampling, and diversion strategies
Use Process Analytical Technology in monitoring and control design
Evaluate validation, deviation, and lifecycle management choices
Prioritize a continuous biomanufacturing implementation roadmap

Course Agenda

Day 1: Continuous Biomanufacturing Architecture

ICH Q13 Integrated Manufacturing Scope Map
Continuous Process Mode Selection Matrix
Therapeutic-Protein Process Flow Architecture
Connected Unit Operation Interface Register
Batch Definition and Run-Time Decision Guide

Day 2: Process Dynamics and Material Traceability

Residence-Time Distribution Model Canvas
Process Disturbance Propagation Map
Material Traceability and Genealogy Method
Sampling Frequency Risk Assessment
Material Diversion Strategy Decision Tree

Day 3: Monitoring and Control Strategy

Critical Quality Attribute Linkage Map
Process Analytical Technology Measurement Plan
Closed-Loop Bioreactor Control Logic
Continuous Downstream Control Strategy
State-of-Control Monitoring Dashboard

Day 4: Validation and Lifecycle Governance

Continuous Process Verification Framework
Long-Run Microbial Control Risk Register
Resin and Membrane Lifetime Evidence Plan
Deviation Detection and Response Workflow
Lifecycle Change and Knowledge Management Plan

Day 5: Continuous Manufacturing Implementation Practice

Exercise: Map an Integrated Therapeutic-Protein Process
Exercise: Interpret Residence-Time Distribution Evidence
Exercise: Design a Monitoring and Diversion Strategy
Exercise: Review a Continuous Process Verification Case
Capstone Exercise: Continuous Biomanufacturing Implementation Dossier

Practical Exercises

The course uses suggested activities from therapeutic-protein, contract manufacturing, and biotechnology production settings.

Suggested activity: connect perfusion, capture, purification, monitoring, hold, and diversion points in an integrated process map.
Suggested activity: use residence-time evidence to trace a disturbance and define sampling and diversion decisions.
Suggested activity: compare control options for upstream variability, downstream capacity, and quality-attribute signals.
Suggested activity: assemble an implementation dossier containing architecture, evidence, controls, validation, and lifecycle actions.

FAQs

Who suits continuous biopharmaceutical manufacturing training, and what does it assume?

Continuous biopharmaceutical manufacturing training suits experienced manufacturing, engineering, science, quality, validation, and transfer functions. It assumes working knowledge of bioprocess operations and manufacturing evidence rather than foundation biotechnology.

How does continuous biopharmaceutical manufacturing training differ from bioreactor scale-up training?

Continuous biopharmaceutical manufacturing training addresses connected upstream and downstream operations, dynamics, traceability, monitoring, diversion, validation, and lifecycle governance. Bioreactor scale-up training concentrates on translating reactor performance and culture conditions across scales.

What does ICH Q13 mean for continuous biopharmaceutical manufacturing?

ICH Q13 provides scientific and regulatory considerations for developing, implementing, operating, and managing continuous manufacturing systems, including applications to therapeutic proteins and directly connected unit operations.

Why is residence-time distribution important in continuous bioprocessing?

Residence-time distribution helps teams relate material movement to disturbances, sampling, traceability, diversion, and batch boundaries. The model and its assumptions require evidence appropriate to the process design.

How is a state of control maintained in continuous biopharmaceutical manufacturing?

A state of control is maintained through defined process limits, suitable measurements, data review, control actions, material-diversion logic, deviation response, and lifecycle verification that together show consistent process performance.

Conclusion

The course integrates ICH Q13, process architecture, dynamics, traceability, analytical technology, control strategy, validation, and lifecycle governance. Participants take back a Continuous Biomanufacturing Implementation Dossier. The dossier aligns technical evidence, monitoring, diversion, validation, and change actions for disciplined implementation decisions.

credits: 5 credit per day

Course Mode: full-time

Provider: Agile Leaders Training Center

Download Brochure (PDF) Print PDF

Showing 1-20 of 57 events

Location	Dates	Duration	Mode	Price
Singapore	Week 45, 2026 2 – 6 November 2026	1 Week	Onsite	€6,500
Lisbon	Week 46, 2026 9 – 13 November 2026	1 Week	Onsite	€6,500
Nairobi	Week 46, 2026 15 – 19 November 2026	1 Week	Onsite	€6,000
London	Week 47, 2026 16 – 20 November 2026	1 Week	Onsite	€6,500
Zoom	Week 49, 2026 30 November – 4 December 2026	1 Week	Online	€3,000
Abu Dhabi	Week 49, 2026 30 November – 4 December 2026	1 Week	Onsite	€6,500
Kuwait	Week 49, 2026 6 – 10 December 2026	1 Week	Onsite	€7,000
Paris	Week 50, 2026 7 – 11 December 2026	1 Week	Onsite	€6,500
Doha	Week 50, 2026 13 – 17 December 2026	1 Week	Onsite	€7,000
Johannesburg	Week 52, 2026 27 – 31 December 2026	1 Week	Onsite	€6,000
Istanbul	Week 01, 2027 4 – 8 January 2027	1 Week	Onsite	€6,000
London	Week 02, 2027 11 – 15 January 2027	1 Week	Onsite	€6,500
Munich	Week 02, 2027 11 – 15 January 2027	1 Week	Onsite	€6,500
Seoul	Week 03, 2027 18 – 22 January 2027	1 Week	Onsite	€12,000
Madrid	Week 05, 2027 1 – 5 February 2027	1 Week	Onsite	€6,500
Montreux	Week 07, 2027 15 – 19 February 2027	1 Week	Onsite	€8,000
Chicago	Week 07, 2027 21 – 25 February 2027	1 Week	Onsite	€16,000
Trabzon	Week 08, 2027 28 February – 4 March 2027	1 Week	Onsite	€8,000
Cairo	Week 09, 2027 1 – 5 March 2027	1 Week	Onsite	€5,200
Tashkent	Week 09, 2027 7 – 11 March 2027	1 Week	Onsite	€8,000

Frequently asked questions

What does this course cover?

OverviewContinuous Biopharmaceutical Manufacturing Training Course is a one-week advanced course for manufacturing managers, process engineers, production scientists, quality professionals, validation staff, and technology-transfer teams who leave with a Continuous Biomanufacturing Implementation Dossier. Participants connect ICH Q13 concepts with integra…

Are training dates available?

Yes. Available dates and destinations are listed in the course dates section on this page.

How can I register?

Choose an available date on this page and complete the registration form, or send a programme enquiry.

Can I download the course brochure?

Yes. Use the brochure download link provided on this page.

Continuous Biopharmaceutical Manufacturing Course